Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 11, 2011, Pages 5185-5193

  Lu, Yu ^a   Zheng, Meiqin ^a   Wang, Bin ^a   Fu, Lei ^a   Zhao, Weijie ^a   Li, Peng ^a   Xu, Jian ^a   Zhu, Hui ^a   Jin, Haixia ^a   Yin, Dali ^b   Huang, Haihong ^b   Upton, Anna M ^c   Ma, Zhenkun ^c  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

^c Global Alliance for TB Drug Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOFAZIMINE DERIVATIVE; ISONIAZID; RIFAMPICIN; TBI 1002; TBI 1004; TBI 1010; TBI 161; TBI 166; TBI 416; TBI 443; TBI 444; TBI 449; TBI 450; TBI 678; TBI 688; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIUM ISOLATE; DRUG ACCUMULATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG STRUCTURE; IN VITRO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

ADMINISTRATION, ORAL; ANIMALS; ANTITUBERCULAR AGENTS; CELL LINE; CERCOPITHECUS AETHIOPS; CLOFAZIMINE; MALE; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS; VERO CELLS;

EID: 80054700266     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00699-11     Document Type: Article

References (46)

1. Adams, L. B., I. Sinha, S. G. Franzblau, J. L. Krahenbuhl, and R. T. Mehta. 1999. Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine. Antimicrob. Agents Chemother. 43: 1638-1643. (Pubitemid 29331240)
2. Anderson, R., A. D. Beyers, J. E. Savage, and A. E. Nel. 1988. Apparent involvement of phospholipase A2, but not protein kinase C, in the prooxidative interactions of clofazimine with human phagocytes. Biochem. Pharmacol. 37:4635-4641. (Pubitemid 19006302)
3. Anderson, R., B. M. Zeis, and I. F. Anderson. 1988. Clofazimine-mediated enhancement of reactive oxidant production by human phagocytes as a possible therapeutic mechanism. Dermatologica 176:234-242.
4. Aplin, R. T., and A. C. McDougall. 1975. Identification of crystals of the rimino-phenazine compound B663 (Lamprene: clofazimine) in mouse spleen macrophages by thin layer chromatography and mass spectrum analysis. Experientia 31:468-469.
5. Bald, D., and A. Koul. 2010. Respiratory ATP synthesis: the new generation of mycobacterial drug targets? FEMS Microbiol. Lett. 308:1-7.
6. Barry, V. C. 1964. The development of chemotherapeutic agent for tuberculosis, p. 46-64. In V. C. Barry (ed.), Chemotherapy of tuberculosis. Butterworths, London, England.
7. Barry, V. C., et al. 1957. A new series of phenazines (rimino-compounds) with high antituberculosis activity. Nature 179:1013-1015.
8. Barry, V. C., and M. L. Conalty. 1965. The antimycobacterial activity of B663. Lepr. Rev. 36:3-7.
9. Bezerra, E. L., M. J. Vilar, P. B. da Trindade Neto, and E. I. Sato. 2005. Double-blind, randomized, controlled clinical trial of clofazimine compared with chloroquine in patients with systemic lupus erythematosus. Arthritis Rheum. 52:3073-3078. (Pubitemid 41447088)
10. Cho, S. H., et al. 2007. Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51:1380-1385. (Pubitemid 46586820)
11. Collins, L., and S. G. Franzblau. 1997. Microplate Alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium. Antimicrob. Agents Chemother. 41:1004-1009. (Pubitemid 27194176)
12. Conalty, M. L. 1964. Methods of preclinical evaluation of antituberculosis drugs, p. 150-174. In V. C. Barry (ed.), Chemotherapy of tuberculosis. Butterworths, London, England.
13. Conalty, M. L., V. C. Barry, and A. Jina. 1971. The antileprosy agent B663 (Clofazimine) and the reticuloendothelial system. Int. J. Lepr. Other Mycobact. Dis. 39:479-492.
14. Conalty, M. L., and R. D. Jackson. 1962. Uptake by reticulo-endothelial cells of the rimino-phenazine B.663(2-P-chloroanilino-5-P-chlorophenyl-3:5- dihydro-3-isopropyliminophenazine). Br. J. Exp. Pathol. 43:651-654.
15. Desikan, K. V., and S. Balakrishnan. 1976. Tissue levels of clofazimine in a case of leprosy. Lepr. Rev. 47:107-113.
16. Garrelts, J. C. 1991. Clofazimine: a review of its use in leprosy and Mycobacterium avium complex infection. DICP 25:525-531.
17. Gatti, J. C., et al. 1970. Treatment of leprosy with a phenazine derivative (B 663 or G 30 320)-clofazimine. Lepr. Rev. 41:89-92.
18. Gomez, J. E., and J. D. McKinney. 2004. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb.) 84:29-44. (Pubitemid 38082931)
19. Huygens, F., J. F. O'Sullivan, and C. E. van Rensburg. 2005. Antimicrobial activities of seven novel tetramethylpiperidine-substituted phenazines against multiple-drug-resistant Gram-positive bacteria. Chemotherapy 51: 263-267. (Pubitemid 41207047)
20. Jagannath, C., M. V. Reddy, S. Kailasam, J. F. O'Sullivan, and P. R. Gangadharam. 1995. Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis: in vitro, intracellular, and in vivo studies. Am. J. Respir. Crit. Care Med. 151:1083-1086.
21. Job, C. K., L. Yoder, R. R. Jacobson, and R. C. Hastings. 1990. Skin pigmentation from clofazimine therapy in leprosy patients: a reappraisal. J. Am. Acad. Dermatol. 23:236-241.
22. Kohanski, M. A., D. J. Dwyer, B. Hayete, C. A. Lawrence, and J. J. Collins. 2007. A common mechanism of cellular death induced by bactericidal antibiotics. Cell 130:797-810. (Pubitemid 47332566)
23. Krajewska, M. M., R. Anderson, and J. F. O'Sullivan. 1993. Effects of clofazimine analogues and tumor necrosis factor-alpha individually and in combination on human polymorphonuclear leukocyte functions in vitro. Int. J. Immunopharmacol. 15:99-111. (Pubitemid 23096235)
24. Lee, S. J., S. A. Wegner, C. J. McGarigle, B. E. Bierer, and J. H. Antin. 1997. Treatment of chronic graft-versus-host disease with clofazimine. Blood 89: 2298-2302. (Pubitemid 27143275)
25. Levy, L. 1974. Pharmacologic studies of clofazimine. Am. J. Trop. Med. Hyg. 23:1097-1109.
26. Levy, L., and H. P. Randall. 1970. A study of skin pigmentation by clofazimine. Int. J. Lepr. Other Mycobact. Dis. 38:404-416.
27. Lu, Y., et al. 2010. A study on the activity of clofazimine with antituberculous drugs against Mycobacterium tuberculosis. Zhonghua Jie He He Hu Xi Za Zhi 33:675-678. (In Chinese.)
28. Lu, Y., et al. 2009. Tissue distribution and deposition of clofazimine in mice following oral administration of isoniazid. Zhonghua Jie He He Hu Xi Za Zhi 32:694-697. (In Chinese.)
29. Lu, Y., et al. 2008. Activities of clofazimine against Mycobacterium tuberculosis in vitro and in vivo. Zhonghua Jie He He Hu Xi Za Zhi 31:752-755. (In Chinese.)
30. Ma, Z., C. Lienhardt, H. McIlleron, A. J. Nunn, and X. Wang. 2010. Global tuberculosis drug development pipeline: the need and the reality. Lancet 375:2100-2109.
31. Mamidi, N. V., A. Rajasekhar, M. C. Prabhakar, and D. R. Krishna. 1995. Tissue distribution and deposition of clofazimine in rat following subchronic treatment with or without rifampicin. Arzneimittelforschung 45:1029-1031.
32. Mansfield, R. E. 1974. Tissue concentrations of clofazimine (B663) in man. Am. J. Trop. Med. Hyg. 23:1116-1119.
33. Moore, V. J. 1983. A review of side-effects experienced by patients taking clofazimine. Lepr. Rev. 54:327-335. (Pubitemid 14152051)
34. Munoz-Elias, E. J., et al. 2005. Replication dynamics of Mycobacterium tuberculosis in chronically infected mice. Infect. Immun. 73:546-551. (Pubitemid 40041149)
35. O'Connor, R., J. F. O'Sullivan, and R. O'Kennedy. 1996. Determination of serum and tissue levels of phenazines including clofazimine. J. Chromatogr. B Biomed. Appl. 681:307-315. (Pubitemid 26193911)
36. O'Sullivan, J. F., M. L. Conalty, and N. E. Morrison. 1988. Clofazimine analogues active against a clofazimine-resistant organism. J. Med. Chem. 31:567-572. (Pubitemid 18070573)
37. Reddy, V. M., G. Nadadhur, D. Daneluzzi, J. F. O'Sullivan, and P. R. Gangadharam. 1996. Antituberculosis activities of clofazimine and its new analogs B4154 and B4157. Antimicrob. Agents Chemother. 40:633-636. (Pubitemid 26075433)
38. Reddy, V. M., J. F. O'Sullivan, and P. R. Gangadharam. 1999. Antimycobacterial activities of riminophenazines. J. Antimicrob. Chemother. 43:615-623.
39. Ren, Y. R., et al. 2008. Clofazimine inhibits human Kv1.3 potassium channel by perturbing calcium oscillation in T lymphocytes. PLoS One 3:e4009.
40. Sanchez, M. R. 2000. Miscellaneous treatments: thalidomide, potassium iodide, levamisole, clofazimine, colchicine, and D-penicillamine. Clin. Dermatol. 18:131-145.
41. Sandler, E. D., V. L. Ng, and W. K. Hadley. 1992. Clofazimine crystals in alveolar macrophages from a patient with the acquired immunodeficiency syndrome. Arch. Pathol. Lab. Med. 116:541-543.
42. U.S. Leprosy Panel (U.S.-Japan Cooperative Medical Science Program) and the Leonard Wood Memorial. 1976. Spaced clofazimine therapy of lepromatous leprosy. Am. J. Trop. Med. Hyg. 25:437-444.
43. Van Deun, A., et al. 2010. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 182:684-692.
44. Van Rensburg, C. E., G. K. Joone, F. A. Sirgel, N. M. Matlola, and J. F. O'Sullivan. 2000. In vitro investigation of the antimicrobial activities of novel tetramethylpiperidine-substituted phenazines against Mycobacterium tuberculosis. Chemotherapy 46:43-48. (Pubitemid 30009333)
45. World Health Organization. 2010. Global tuberculosis control. World Health Organization, Geneva, Switzerland.
46. Yano, T., et al. 2011. Reduction of clofazimine by mycobacterial type 2 NADH-quinone oxidoreductase: a pathway for the generation of bactericidal levels of reactive oxygen species. J. Biol. Chem. 286:10276-10287.